Paul Maddison

List of Publications by Year
in descending order

52 papers	3,056 citations	257101 24 h-index	243296 44 g-index
52 all docs	52 docs citations	52 times ranked	2827 citing authors

#	Article	IF	Citations
1	Forecasting stroke-like episodes and outcomes in mitochondrial disease. Brain, 2022, 145, 542-554.	3.7	25
2	Splicing in two skeletal muscle transcripts correlates with clinical phenotype in myotonic dystrophy type 1 patients. Journal of Neurology, 2022, , 1.	1.8	0
3	Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurology, The, 2022, 21, 176-188.	4.9	74
4	Prospective study of cancer survival in patients with HuD-antibody-associated paraneoplastic neurological disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1350-1351.	0.9	4
5	Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort. Scientific Reports, 2020, 10, 10546.	1.6	8
6	Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome. Journal of Neuroimmunology, 2020, 340, 577149.	1.1	8
7	Human hippocampal CA3 damage disrupts both recent and remote episodic memories. ELife, 2020, 9, .	2.8	37
8	A Prospective Study of the Incidence of Myasthenia Gravis in the East Midlands of England. Neuroepidemiology, 2019, 53, 93-99.	1.1	24
9	False-positive acetylcholine receptor antibody results in patients without myasthenia gravis. Journal of Neuroimmunology, 2019, 332, 69-72.	1.1	14
10	The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders. Journal of Neuroimmunology, 2019, 326, 14-18.	1.1	12
11	MT-ND5 Mutation Exhibits Highly Variable Neurological Manifestations at Low Mutant Load. EBioMedicine, 2018, 30, 86-93.	2.7	47
12	Lambertâ€"Eaton myasthenic syndrome and cerebellar ataxia: is Response to immunotherapy a clue to pathogenesis?. Muscle and Nerve, 2018, 58, 4-6.	1.0	1
13	A diagnostic conundrum. Practical Neurology, 2018, 18, 137-142.	0.5	1
14	Ocular presentation of myasthenia gravis: A natural history cohort. Muscle and Nerve, 2018, 57, 622-627.	1.0	19
15	The Association of British Neurologists' myasthenia gravis guidelines. Annals of the New York Academy of Sciences, 2018, 1412, 166-169.	1.8	21
16	Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain, 2018, 141, 2263-2271.	3.7	100
17	Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis. Journal of Neuroimmunology, 2018, 321, 164-170.	1.1	31
18	TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations. Journal of Clinical Investigation, 2018, 128, 1164-1177.	3.9	75

#	Article	IF	Citations
19	Body composition and clinical outcome measures in patients with myotonic dystrophy type 1. Neuromuscular Disorders, 2017, 27, 286-289.	0.3	15
20	Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 353-361.	0.9	124
21	Effects of aspirin on small-cell lung cancer mortality and metastatic presentation. Lung Cancer, 2017, 106, 67-69.	0.9	9
22	Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology, 2017, 88, 1334-1339.	1.5	62
23	The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research. Journal of Neurology, 2017, 264, 979-988.	1.8	23
24	Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis. Brain, 2017, 140, 1212-1219.	3.7	89
25	Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness. Orphanet Journal of Rare Diseases, 2017, 12, 173.	1.2	21
26	1712â€…â€˜Less contented as a personâ€™: preliminary data from the lgi1-qol study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A7.1-A7.	0.9	0
27	Autoantibodies to glutamic acid decarboxylase in patients with epilepsy and their relationship with type 1 diabetes: a pilot study: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 676-677.	0.9	5
28	Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study. PLoS ONE, 2015, 10, e0143558.	1.1	28
29	Paraneoplastic neurologic disorders in small cell lung carcinoma. Neurology, 2015, 85, 235-239.	1.5	99
30	Clinical and Pathological Features of Mitochondrial DNA Deletion Disease Following Antiretroviral Treatment. JAMA Neurology, 2015, 72, 603.	4.5	3
31	Myasthenia gravis: Association of British Neurologistsâ€™ management guidelines. Practical Neurology, 2015, 15, 199-206.	0.5	127
32	RETROGRADE AMNESIA FOLLOWING AUTOIMMUNE LIMBIC ENCEPHALITIS. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.79-e4.	0.9	0
33	Autoantibodies in the Lambert-Eaton Myasthenic Syndrome (LEMS) and Amyotrophic Lateral Sclerosis (ALS). , 2014, , 629-636.		0
34	Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain, 2014, 137, 2178-2192.	3.7	430
35	Lambert-Eaton Myasthenic Syndrome. , 2014, , 1089-1099.		0
36	Clinical and Myopathological Characteristics of Desminopathy Caused by a Mutation in Desmin Tail Domain. European Neurology, 2012, 68, 279-286.	0.6	13

#	Article	IF	Citations
37	Treatment in Lambertâ€“Eaton myasthenic syndrome. Annals of the New York Academy of Sciences, 2012, 1275, 78-84.	1.8	29
38	Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS. Journal of Clinical Oncology, 2011, 29, 902-908.	0.8	210
39	The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 671-673.	0.9	107
40	Immunobiomarkers in Small Cell Lung Cancer: Potential Early Cancer Signals. Clinical Cancer Research, 2011, 17, 1474-1480.	3.2	87
41	Prospective Study of Lambert-Eaton Myasthenic Syndrome in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1309-1310.	0.5	1
42	Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer, 2010, 70, 335-339.	0.9	43
43	Which antibody and which cancer in which paraneoplastic syndromes?. Practical Neurology, 2010, 10, 260-270.	0.5	59
44	Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer. Journal of Neuroimmunology, 2008, 201-202, 159-162.	1.1	40
45	Neuromyotonia. Clinical Neurophysiology, 2006, 117, 2118-2127.	0.7	139
46	Clinical electrophysiological characterization of the acquired neuromyotonia phenotype of autoimmune peripheral nerve hyperexcitability. Muscle and Nerve, 2006, 33, 801-808.	1.0	53
47	Neurology training in the United Kingdom: a diagnostic analysis of over 5000 patients. Journal of Neurology, 2005, 252, 605-607.	1.8	11
48	Treatment for Lambert-Eaton myasthenic syndrome. , 2005, , CD003279.		38
49	Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain, 2002, 125, 1887-1895.	3.7	419
50	Strength-duration properties of peripheral nerve in acquired neuromyotonia. , 1999, 22, 823-830.		45
51	Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet, The, 1999, 353, 117-118.	6.3	208
52	Acquired neuromyotonia in a patient with spinal epidural abscess. , 1998, 21, 672-674.		18